Register to submit your paper, and Start Earning from your Research Articles
Share Your Oncology Research — Publish and Earn
In the rapidly evolving world of cancer research and oncology, timely knowledge sharing can make a real difference in patient outcomes and therapeutic development. Whether you're studying tumor biology, clinical oncology, or cutting-edge immunotherapy techniques, our multidisciplinary publishing platform provides an open space for your discoveries — with monetization opportunities built-in.
Why Publish Oncology Articles with Us?
Traditional peer review can delay the visibility of important oncology findings. Our non-peer-reviewed model allows you to share impactful cancer research directly and rapidly with fellow researchers, medical professionals, and healthcare innovators worldwide. From lab studies to clinical observations, your work can reach the audience it deserves.
From Benchside Discovery to Bedside Impact
Cancer research drives breakthroughs in early detection, treatment protocols, and patient care. Whether your focus is on genomics, targeted therapies, or epidemiological cancer trends, our platform invites contributions from all corners of the oncology community. Your work can inform real-world decisions and fuel future research directions.
Monetize Your Expertise
Publishing isn't only about academic recognition; it's also about earning value for your efforts. Our platform gives oncology researchers the option to monetize their content while contributing to the global cancer research conversation. If you're seeking an alternative to conventional medical journals, this is your invitation to submit.
Join a growing network of oncologists, cancer research specialists, and medical writers. Submit your oncology articles today and turn your insights into both impact and income.
Hung-Chia Chen,
Hung-Chia Chen
Institution:
Email:
James J Chen
James J Chen
Institution:
Email:
Background
Two key considerations in evaluating survival prediction models are predictability (the ability to accurately predict survival risks) and reproducibility (the ability to generalize predictions across studies or centers). This study explores approaches to assessing the reproducibility of survival risk predictions across medical...
4 months ago
Seema A. Khan
Seema A. Khan
Institution: Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicaqgo, Illinois
Email:
This article addresses the role of progesterone exposure in breast cancer risk, focusing on both biological and technical barriers in studying progesterone’s impact. Research indicates that higher progesterone levels in postmenopausal women may modestly increase breast cancer risk, with a stronger association for invasive breast cancers. The study also highlights the complex relationship between...
6 months ago
Vasily Giannakeas
Vasily Giannakeas
Institution: Women’s College Research Institute, Toronto, Ontario, Canada
Email:
Canonical predictors for the prognosis of breast cancer include estrogen receptor (ER), progesterone receptor (PR), and ERBB2 (formerly HER2) receptor. In most cases, positive ER status is auspicious, but there are exceptions (young women, black women, and BRCA2 mutation carriers). The simplest designation, hormone receptor–positive cancers, includes tumors that express ER and/or PR (hormone rec...
6 months ago
Ofer N. Gofrit,
Ofer N. Gofrit
Institution:
Email:
Ariel Aviv
Ariel Aviv
Institution:
Email:
Cancer is a consequence of stochastic (mutations, genetic, and epigenetic instabilities) and deterministic (evolutionary bottlenecks) events. Stochastic events are less amenable to prediction, whereas deterministic events yield more predictable results. The relative contribution of these opposing forces determines cancer predictability, which affects the accuracy of our prognostic predictions and ...
6 months ago
Jordon B. Ritchie,
Jordon B. Ritchie
Institution: NULL
Email:
Cecelia Bellcross,
Cecelia Bellcross
Institution: NULL
Email:
Caitlin G. Allen,
Caitlin G. Allen
Institution: NULL
Email:
Lewis Frey,
Lewis Frey
Institution: NULL
Email:
Heath Morrison,
Heath Morrison
Institution: NULL
Email:
Joshua D. Schiffman,
Joshua D. Schiffman
Institution: NULL
Email:
Brandon M. Welch
Brandon M. Welch
Institution: NULL
Email:
Background
Family health history (FHx) is an effective tool for identifying patients at risk of hereditary cancer. Hereditary cancer clinical practice guidelines (CPG) contain criteria used to evaluate FHx and to make recommendations for genetic consultation. Comparing different CPGs used to evaluate a common set of FHx provides insight into how well the CPGs perform, the extent of agreement acro...
6 months ago
Nicole Uzzo,
Nicole Uzzo
Institution: NULL
Email:
Matthew Loecher,
Matthew Loecher
Institution: NULL
Email:
Robert G. Uzzo,
Robert G. Uzzo
Institution: NULL
Email:
Daniel D. Eun
Daniel D. Eun
Institution: NULL
Email:
Introduction: Active surveillance has become a standard of care for the management of small renal masses. Decision to transition from surveillance to intervention relies on several factors including growth kinetics, histologic grade on biopsy and patient comorbidities. Management of renal masses in pregnancy presents a unique change when clinical triggers must be weighed with risk to fetus. We pre...
6 months ago
zulqarnain bhalwal
zulqarnain bhalwal
Institution: NULL
Email:
Summary
Hereditary cancer syndromes are inherited conditions that increase the risk of cancer, affecting 5-10% of cases. Key factors for identifying high-risk patients include personal/family cancer history and genetic mutations. Management strategies involve surveillance (screening), risk reduction (lifestyle changes, surgery), and chemoprevent...
6 months ago
Marek Olakowski,
Marek Olakowski
Institution: NULL
Email:
Łukasz Bułdak
Łukasz Bułdak
Institution: NULL
Email:
Background
It is estimated that about 10% of pancreatic cancer cases have a genetic background. People with a familial predisposition to pancreatic cancer can be divided into 2 groups. The first is termed hereditary pancreatic cancer, which occurs in individuals with a known hereditary cancer syndrome caused by germline single gene mutations (e.g.,BRCA1/2,CDKN2A). The second is considered as fami...
6 months ago
Swati G. Patel,
Swati G. Patel
Institution: NULL
Email:
Heather Hampel,
Heather Hampel
Institution: NULL
Email:
Derek Smith,
Derek Smith
Institution: NULL
Email:
Dexiang Gao,
Dexiang Gao
Institution: NULL
Email:
Myles Cockburn,
Myles Cockburn
Institution: NULL
Email:
Fay Kastrinos
Fay Kastrinos
Institution: NULL
Email:
Background: 16–25% of colorectal cancers (CRCs) diagnosed under age 50 are associated with hereditary cancer syndromes. Advanced adenomas are considered precursors to CRC. Although polyp removal prevents cancer, polypectomy does not change underlying genetic risk. Patients with isolated advanced polyps do not currently qualify for genetic testing unless they have a personal or family history of ...
6 months ago
A. K. Prabodhana Ranaweera,
A. K. Prabodhana Ranaweera
Institution: NULL
Email:
D. Hettiarachchi,
D. Hettiarachchi
Institution: NULL
Email:
K. W. Gunawardena,
K. W. Gunawardena
Institution: NULL
Email:
M. D. S. Lokuhetty,
M. D. S. Lokuhetty
Institution: NULL
Email:
V. H. W. Dissanayake
V. H. W. Dissanayake
Institution: NULL
Email:
Introduction: Hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC) is a rare autosomal dominantly inherited cancer predisposing syndrome giving rise to cutaneous and uterine leiomyomatosis, leiomyosarcoma and renal cell cancer. Patients with this syndrome harbours germline pathogenic variants in the fumarate hydratase (FH) gene. Case presentation: A 28-year-old Sri Lankan female, a pro...
6 months ago